AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two segments, Insurance and Reinsurance. The Insurance segment offers professional insurance products that cover directors' and officers' liability, errors and omissions, employment practices, fiduciary, crime, professional indemnity, medical malpractice, and other financial insurance related coverages for commercial enterprises, financial institutions, not-for-profit organizations, and other professional service providers; and property insurance products for commercial buildings, residential premises, construction projects, property in transit, onshore renewable energy installations, and physical damage and business interruption following an act of terrorism. This segment also provides marine and aviation insurance services for offshore energy, offshore renewable energy, cargo, liability, including kidnap and ransom, fine art, specie, and hull war, hull and liability, and specific war coverage for passenger airlines, cargo operations, general aviation operations, airports, aviation authorities, security firms, and  product manufacturers; personal accident, travel insurance, specialty health products for employer and affinity groups, and pet insurance products; and liability, cyber, and credit and political risk insurance services. The Reinsurance segment offers agriculture, marine and aviation, catastrophe, accidental and health, credit and surety, motor, professional, travel, life, engineering, property, and liability reinsurance products. AXIS Capital Holdings Limited was founded in 2001 and is headquartered in Pembroke, Bermuda.

AXIS Capital Holdings Limited

In a report released yesterday, Sean Laaman from Morgan Stanley reiterated a Hold rating on Axsome Therapeutics, with a price target of $251.00. Th...

Axsome Therapeutics (AXSM) Receives a Hold from Morgan Stanley

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Heron Therapeutics (HRTX), Aquestive Therapeutics (AQST) and Axso...

Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Aquestive Therapeutics (AQST) and Axsome Therapeutics (AXSM)

RBC Capital analyst Rowland Mayor maintained a Buy rating on Axis Capital on July 29 and set a price target of $130.00. The company’s shares closed...

RBC Capital Sticks to Its Buy Rating for Axis Capital (AXS)

In a report released yesterday, Charlie Lederer from BMO Capital maintained a Hold rating on Axis Capital, with a price target of $108.00. The comp...

BMO Capital Sticks to Their Hold Rating for Axis Capital (AXS)

Analysts have been eager to weigh in on the Financial sector with new ratings on Trustmark (TRMK), Axis Capital (AXS) and MSCI (MSCI). Trustmark (T...

Analysts Offer Insights on Financial Companies: Trustmark (TRMK), Axis Capital (AXS) and MSCI (MSCI)

Analysts are intrested in these 5 stocks: ( ($AXSM) ), ( ($FIVE) ), ( ($APPS) ), ( ($INTU) ) and ( ($ADBE) ). Here is a breakdown of their recent


Axsome, Five Below, APPS, Intuit, Adobe Trending With Analysts

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. The Phase 3 study “An Open-Label Study to Assess the Long-Ter...

Axsome Advances AXS-14 Fibromyalgia Trial With New Long-Term Safety Update

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Axsome Therapeutics, Inc. is running a Phase 3 study called C...

Axsome’s CLARITY Trial Targets Sleepy Depression: What Investors Should Watch

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Axsome Therapeutics, Inc. is running a late-stage study calle...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXS	$99.88	-1.30%	510.68K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXS	$99.88	-1.3%	510.68K
3
4
5
6

AXS

Get AXIS Capital Holdings Limited Data in Excel

Get AXIS Capital Holdings Limited Data in Excel